secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2024-07-16T23:59:59+00:00
Accession:  0001854270-24-000091
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Biosciences amends ChEF purchase agreement to allow intraday VWAP share sales under $50M facility
--------------------------------------------------------------------------------

- Entered amended ChEF purchase agreement with Chardan Capital Markets for existing $50M equity facility.
- Amendment permits intraday volume-weighted average price (VWAP) purchases of common stock.
- The change gives the company flexibility to sell shares more frequently under the facility.
- Shares sold under the agreement are restricted securities and resale registered under Registration Rights Agreement.
- The Agreement amends and restates the original August 31, 2022 ChEF Purchase Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000091/0001854270-24-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427024000091/snti-20240716.htm
  HTML page:      https://secwatch.observer/filing/0001854270-24-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer